Septum-guided segmentectomy for small lung cancer deep in the lung

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a small, early-stage lung cancer (non-small cell) that sits deep inside the lung. They would have surgery to remove only a segment of the lung.

Age

18 to 80 years

Sex

All sexes can join.

Disease stage

Clinical stage IA (cT1a-bN0M0). Tumor 2 cm (0.8 in) or smaller across, mostly solid (CTR > 0.5), with its center in the inner 2/3 of the lung field on CT views.

Earlier treatment

No earlier lung surgery on the same side of the chest.

Main reasons for not taking part

• Several lung nodules, or cancer that has spread to distant parts of the body
• Cancer found in lymph nodes (N1/N2) or spread in the lung lining during surgery
• Another cancer within the past 5 years
• Severe heart or brain blood vessel disease that makes surgery unsafe
• Pregnant or breastfeeding

The registry criteria, word for word

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

• Are you between 18 and 80 years old?YesNo

What the trial wants to find out

The purpose of this study is to evaluate the safety and effectiveness of a specialized surgical technique called "Septum-guided Segmentectomy" for treating early-stage lung cancer located deep within the lung tissue.Standard surgery for lung cancer often involves removing an entire lung lobe (lobectomy), which can significantly reduce a patient's breathing capacity. For small tumors, removing only a segment of the lung (segmentectomy) can preserve more healthy tissue. However, for tumors located deep in the lung, traditional segmentectomy is technically challenging and risks leaving cancer cells behind.In this study, surgeons will use the natural anatomical boundaries-the intersegmental veins and their surrounding thin membranes (septa)-as a guide to precisely remove the target lung segment. This "septum-guided" approach aims to ensure the cancer is completely removed while maximizing the preservation of healthy lung function.Participants will be followed for 3 years after surgery to monitor for cancer recurrence and assess their long-term recovery.

The group in the trial

• Septum-guided SegmentectomyTreatment being tested

  Participants with solid-dominant, deep-seated early-stage NSCLC will undergo septum-guided segmentectomy. The core technique involves identifying and utilizing the intersegmental veins and their surrounding fibrous septa as the anatomical boundaries for precise resection. Systemic lymph node sampling or dissection (at least 3 hilar and 3 mediastinal groups) is mandatory for all patients. An intraoperative second registration will be performed to ensure the oncological appropriateness of the procedure before resection.